BT and Accelrys Technologies Unlock Value in Big Data - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BT and Accelrys Technologies Unlock Value in Big Data


British Telecommunications (BT) and Accelrys are collaborating to provide solutions for analyzing massive datasets using BT for Life Sciences Cloud Compute Platform combined with Accelrys Enterprise Platform and Accelrys Pipeline Pilot software, the companies announced in a press release.  The tools can be used to mine information on healthcare topics from very large datasets.

BT has collated publically available health system and social care information into a research repository intended for use by the life sciences and healthcare industries as well as academia, initially hosted in the United States and United Kingdom, but available for global access. Such data can provide valuable insight into a number of healthcare topics, such as disease prevalence, impact of ethnic mix and adverse drug reactions. However, the information is often contained in very large datasets and may be unstructured in nature. The datasets can be analyzed using the BT and Accelrys tools.

“The generation of ever-increasing amounts of health data is both a blessing and a curse, as they are data-rich, but often information-poor,” said Leif Pedersen, senior vice president of marketing, product management and corporate development at Accelrys, in the press release. “Working with BT, we’ve shown that we can deliver meaningful and valuable insights from these huge datasets.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here